TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21775977

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture
Number of subjects: 47
Study: 19216017

Group type: EXPERIMENTAL
Intervention: Reading a text description of the map
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touching a wooden topological representation of the map
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both reading and touching the map
Number of subjects: 0
Study: 16981050

Group type: EXPERIMENTAL
Intervention: Rheumazin (10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine, 2.5 mg cyanocobalamin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Feldene (20 mg piroxicam)
Number of subjects: 80
Study: 12428781

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for depression (CBT-D)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 179
Study: 10453768

Group type: EXPERIMENTAL
Intervention: Systematic multicomponent rehabilitation strategy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study: 8652960

Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10% Intralipid
Number of subjects: 37
Study: 2221287

Group type: EXPERIMENTAL
Intervention: Hazelden‐type treatment (N = 74)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Traditional‐type treatment (N = 67)
Number of subjects: 141
Study: 349319

Group type: EXPERIMENTAL
Intervention: Labetalol (600 mg twice a day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prindolol (15 mg twice a day) plus Hydralazine (50 mg three times a day)
Number of subjects: 14
Study: 30028640

Group type: EXPERIMENTAL
Intervention: Test formulation of itraconazole 100 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference formulation of itraconazole 100 mg
Number of subjects: 38
Study: 26162769

Group type: EXPERIMENTAL
Intervention: Needs-based patient education using the Educational Needs Assessment Tool (ENAT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (CG) received patient education without ENAT
Number of subjects: 132
Study: 24700130

Group type: EXPERIMENTAL
Intervention: Peer teaching and peer assessment (Group II)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Physician assessment (Group II)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Physician training and assessment (Group I)
Number of subjects: 248
Study: 23545864

Group type: EXPERIMENTAL
Intervention: Intervention group with rSO 2 monitoring and specific interventions for cerebral desaturation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with continuous rSO 2 monitoring without intervention
Number of subjects: 100
Study: 19602188

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment: three sets of 60 s of vibration (30 Hz, +/-4 mm) while standing in a semi-squat position
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control treatment: static squat
Number of subjects: 24
Study: 17703885

Group type: EXPERIMENTAL
Intervention: Pregabalin (150, 300, and 600mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16184919

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for colorectal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery for colorectal cancer
Number of subjects: 0
Study: 11963384

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 9509207

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 8594956

Group type: EXPERIMENTAL
Intervention: Directional 22-gauge Sprotte needle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-directional 22-gauge Quincke needle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cranially directed catheters
Number of subjects: 40
Study: 2197898

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg induction and 0.15 mg/kg per min maintenance with N2O/O2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg induction and enfluran maintenance with N2O/O2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopental induction until loss of eyelash reflex and enfluran maintenance with N2O/O2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (both techniques)
Number of subjects: 30
Study: 921082

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to controls
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients at the time of chemotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients between chemotherapy courses
Number of subjects: 42
Study: 31331617

Group type: EXPERIMENTAL
Intervention: LSD 6.5 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LSD 13 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LSD 26 μg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0 μg)
Number of subjects: 20
Study: 28936608

Group type: EXPERIMENTAL
Intervention: 1.0‐msec pulse width
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1‐msec pulse width
Number of subjects: 20
Study: 25693988

Group type: EXPERIMENTAL
Intervention: Dyad practice (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-student practice (n = 14)
Number of subjects: 30
Study: 24666664

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional short-acting opioid
Number of subjects: 130
Study: 22964692

Group type: EXPERIMENTAL
Intervention: Non-alcoholic steatohepatitis (NASH)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 162
Study: 19404938

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 794

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 794

Group type: COMPARATOR
Intervention: Adalimumab alone
Number of subjects: 794
Study: 17329667

Group type: EXPERIMENTAL
Intervention: Satellite TV training
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Training plus technical assistance
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 415
Study: 15220947

Group type: COMPARATOR
Intervention: NUTRIOSE FB 30 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 60 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 80 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 10 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB 15 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB (all doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NUTRIOSE FB (up to 45 g/day)
Number of subjects: 20
Study: 11898516

Group type: EXPERIMENTAL
Intervention: Various tic-suppressing treatments including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery; specific dosages and durations not available.
Number of subjects: 0
Study: 9850434

Group type: EXPERIMENTAL
Intervention: Patented soft gelatine capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hard shell capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Number of subjects: 12
Study: 8115666

Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg, intramuscular injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (500 mg, intravenous injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (2 mg, intravenous injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 30193574

Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: C‐MAC videolaryngoscope
Number of subjects: 50
Study: 26602586

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma at the time of distraction
Number of subjects: 14

Group type: COMPARATOR
Intervention: Distraction only (Control group)
Number of subjects: 14
Study: 24265356

Group type: EXPERIMENTAL
Intervention: Bleach baths plus routine hygienic measures
Number of subjects: 987

Group type: COMPARATOR
Intervention: Routine hygienic measures alone
Number of subjects: 987
Study: 22898716

Group type: EXPERIMENTAL
Intervention: Progressive hypertrophic resistance training (RT) for 21 weeks
Number of subjects: 39
Study: 19650782

Group type: EXPERIMENTAL
Intervention: Bright light exposure (10,000 lux)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Levothyroxine (64 nmol) and Liothyronine (16 nmol) supplement
Number of subjects: 85

Group type: COMPARATOR
Intervention: Dim light exposure (50 lux)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 85
Study: 19816018

Group type: EXPERIMENTAL
Intervention: Neuroaid (MLC 601), 4 capsules 3 times a day for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, 4 capsules 3 times a day for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neuroaid (MLC 601)
Number of subjects: 40
Study: 16621658

Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) monotherapy
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 15599534

Group type: COMPARATOR
Intervention: Liposuction
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 therapy after liposuction (2 weekly applications for 10 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 therapy alone (2 weekly applications for 10 weeks)
Number of subjects: 42
Study: 10786744

Group type: EXPERIMENTAL
Intervention: Dopexamine at 0.5 microg kg(‐1) min(‐1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dopexamine at 2.0 microg kg(‐1) min(‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dopexamine (both dosages)
Number of subjects: 21
Study: 9483214

Group type: EXPERIMENTAL
Intervention: bcl‐2 oncoprotein
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: L‐myc oncoprotein
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: p53 mutated gene oncoprotein
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rb gene oncoprotein
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IGFII
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IGFIBP3
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ki‐67 positive cells
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CD44 types 5 and 6
Number of subjects: 104
Study: 8311568

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg body weight over 3 days)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg base/kg body weight over 3 days)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Quinine (8 mg/kg every 8 h for 3 or 5 days)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (25-1.25 mg/kg, in one dose)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 166
Study: 3752341

Group type: EXPERIMENTAL
Intervention: Resistive training with muscle stimulation (last 12 sessions of 24 total sessions)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resistive training alone (24 sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 31329828

Group type: EXPERIMENTAL
Intervention: Enhanced nutritional support pathway including extended preoperative nutritional support and one month home enteral nutrition (HEN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional nutritional support
Number of subjects: 50
Study: 29521887

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL), 6 hours (2 hours weekly for 3 weeks)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Lecture-style classes, 6 hours (2 hours weekly for 3 weeks)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 183
Study: 26849477

Group type: COMPARATOR
Intervention: Soccer exercise
Number of subjects: 107

Group type: COMPARATOR
Intervention: Zumba exercise
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 107
Study: 24676848

Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV) - 20 min daily, 35 Hz, 0.3 g, 5 days/week for 18 months
Number of subjects: 710

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV)
Number of subjects: 710
Study: 22172728

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20671901

Group type: EXPERIMENTAL
Intervention: Training of primary health care staff in mental health integration
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Training of supervisors (psychiatrists, psychiatric nurses, district public health nurses)
Number of subjects: 3000
Study: 18386103

Group type: EXPERIMENTAL
Intervention: Patient-specific reminders mailed to physicians
Number of subjects: 717

Group type: COMPARATOR
Intervention: No reminders to physicians (Control)
Number of subjects: 717
Study: 16060962

Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 11949911

Group type: EXPERIMENTAL
Intervention: Minnesota Family Investment Program (MFIP)
Number of subjects: 879
Study: 10087643

Group type: EXPERIMENTAL
Intervention: Disgust mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonphobic participants)
Number of subjects: 0
Study: 7583899

Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine-morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine-morphine
Number of subjects: 0
Study: 2182976

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25‐(OH)2D3)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7025769

Group type: EXPERIMENTAL
Intervention: Cefamandole (Group II)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Cefamandole plus carbenicillin (Group III)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 136
Study: 31512448

Group type: EXPERIMENTAL
Intervention: Isokinetic group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 27573416

Group type: EXPERIMENTAL
Intervention: Make a Move intervention
Number of subjects: 0
Study: 26578668

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2279

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2279
Study: 23833960

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (patients without AD)
Number of subjects: 36
Study: 23007280

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 154
Study: 19181448

Group type: EXPERIMENTAL
Intervention: Schedule II opioids (strong opioids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any type of opioid prescriptions for >or=90 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schedule II opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: No opioid prescriptions
Number of subjects: 0
Study: 17188618

Group type: EXPERIMENTAL
Intervention: Oral steroids and oral cyclophosphamide (CYC) (maximum total dose 150 mg/kg) followed by oral methotrexate (MTX) (12.5 mg/m(2)/week) for maintenance.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral steroids and methotrexate (MTX) (12.5 mg/m(2)/week).
Number of subjects: 6
Study: 15534533

Group type: EXPERIMENTAL
Intervention: Fluoroscopy‐based computer navigation system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 50
Study: 11331315

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (HDI) for 1 year
Number of subjects: 880

Group type: COMPARATOR
Intervention: GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks
Number of subjects: 880
Study: 9205817

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zolmitriptan (3.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral tablet of zolmitriptan (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Administration of 25 mg [14C]-zolmitriptan capsule
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous dosing of zolmitriptan
Number of subjects: 12
Study: 8434963

Group type: EXPERIMENTAL
Intervention: NK 622 (toremifene citrate) 40 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 57
Study: 3660148

Group type: EXPERIMENTAL
Intervention: Neonatalyte (Sabax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study: 30992334

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (LDSH)
Number of subjects: 2416
Study: 29402816

Group type: EXPERIMENTAL
Intervention: Adjuvant rTMS (5 times a week for 30 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham condition (5 times a week for 30 min)
Number of subjects: 12
Study: 26457101

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (Respivol) for 8 weeks (15 min/day for 6 days/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (Respivol)
Number of subjects: 30
Study: 23410986

Group type: EXPERIMENTAL
Intervention: VES‐ODT (orally disintegrating tablet)
Number of subjects: 30

Group type: COMPARATOR
Intervention: VES‐CT (conventional tablet)
Number of subjects: 30
Study: 20716398

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 630

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 630
Study: 19846545

Group type: EXPERIMENTAL
Intervention: High-normal arterial pH (7.43-7.45)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-normal arterial pH (7.36-7.38)
Number of subjects: 8
Study: 17075402

Group type: EXPERIMENTAL
Intervention: Postoperative debridement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (saline irrigation only)
Number of subjects: 60
Study: 14998427

Group type: EXPERIMENTAL
Intervention: 3-day training program on rational pharmacotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 25
Study: 11463766

Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion (10(-10), 10(-9), and 10(-8) mol/min for 5 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: N(G)-monomethyl-L-arginine (nitric oxide synthesis inhibitor)
Number of subjects: 16
Study: 9990418

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 105

Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 105
Study: 8065201

Group type: EXPERIMENTAL
Intervention: Back up pressure ventilation with facial mask (BUPM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 18
Study: 2567745

Group type: EXPERIMENTAL
Intervention: Performance-based treatment for some phobic areas
Number of subjects: 27
Study: 4909766

Group type: EXPERIMENTAL
Intervention: High oral doses of marihuana extract (1 (‐)‐Delta(1)‐tetrahydrocannabinol)
Number of subjects: 0
Study: 31060845

Group type: EXPERIMENTAL
Intervention: Modified 2-rescuer CPR technique with a 2-handed mask seal
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard 2-rescuer CPR
Number of subjects: 94
Study: 28025037

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin with azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam after tobramycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled tobramycin without azithromycin
Number of subjects: 0
Study: 26234407

Group type: EXPERIMENTAL
Intervention: Lactococcus lactis ssp. lactis JCM5805 yogurt
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 213
Study: 22646754

Group type: EXPERIMENTAL
Intervention: Intervention group with implemented delirium guidelines
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group without implemented delirium guidelines
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study: 21248785

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Dual therapies (valsartan/hydrochlorothiazide, amlodipine/valsartan, amlodipine/hydrochlorothiazide)
Number of subjects: 2271
Study: 17971827

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (30 mg) with micronutrients
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (30 mg) without micronutrients
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo control (PlbCON)
Number of subjects: 250
Study: 17380489

Group type: EXPERIMENTAL
Intervention: 10 cm2 rivastigmine patch
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: 20 cm2 rivastigmine patch
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: 12 mg/day rivastigmine capsules
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: All patch sizes (5, 10, 15, and 20 cm2)
Number of subjects: 1195
Study: 15126761

Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing aid fitting
Number of subjects: 94